Quarterly ResultAug 13, 2026, 04:18 PM
Quantum Biopharma Narrows H1 Loss to $16.85M; Cash Up to $3.65M
AI Summary
Quantum Biopharma Ltd. reported a reduced net loss of $16.85 million for the first half of 2026, an improvement from $18.51 million in the prior year. The company significantly increased its cash and cash equivalents to $3.65 million and digital assets to $5.89 million. Operating expenses decreased, and cash used in operating activities was notably lower. The company continues its biopharmaceutical R&D and has expanded its treasury to include cryptocurrency investments.
Key Highlights
- Net loss for H1 2026 decreased to $16.85 million from $18.51 million in H1 2025.
- Cash and cash equivalents increased to $3.65 million as of June 30, 2026, from $1.91 million at year-end 2025.
- Digital assets grew to $5.89 million as of June 30, 2026, from $2.21 million at year-end 2025.
- Total operating expenses for H1 2026 decreased to $5.26 million from $8.25 million in H1 2025.
- Cash provided by financing activities for H1 2026 significantly increased to $9.46 million from $4.42 million in H1 2025.
- Net loss per share for H1 2026 improved to $(3.02) from $(6.73) in H1 2025.
- Company no longer holds loans secured by residential properties as of June 30, 2026.
- Ownership interest in Unbuzzd Wellness Inc. decreased to 19.48% as of June 30, 2026.
Price Impact
More from QNTM